AIM ImmunoTech(AIM) - 2025 Q4 - Annual Report

Clinical Development - AIM ImmunoTech is focusing its efforts on developing Ampligen for late-stage pancreatic cancer, which presents a significant market opportunity due to over 450,000 deaths worldwide in 2022[13] - The ongoing Phase 2 clinical trial (DURIPANC study) is evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer, with 18 patients enrolled so far[14] - The company has established a partnership with Thermo Fisher Scientific to design a Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer[15] - AIM is exploring Ampligen's potential as a treatment for post-COVID conditions, with a Phase 2 study involving 80 subjects completed in February 2024[21] - The company is also investigating Ampligen's use as a vaccine adjuvant in combination with AstraZeneca's FluMist for enhanced immune response against avian influenza[20] - Ampligen has shown promising results in pre-clinical studies for various viral infections, including COVID-19, with significant impacts on viral replication observed[19] - Ongoing clinical trials include the DURIPANC study, which combines Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, showing promising results with 21% of subjects achieving progression-free survival over 6 months[68] - The Phase 2 AMP-270 clinical trial aims to compare Ampligen with standard care in advanced pancreatic adenocarcinoma, with approximately 90 subjects expected to enroll across 30 centers[70] - A Phase 2 study of Ampligen in advanced recurrent ovarian cancer reported an Objective Response Rate of 45% in platinum-sensitive subjects, with a median Progression-Free Survival of 7.8 months[73] - The Phase 1 study for early-stage triple negative breast cancer showed a primary endpoint of safety and tolerability was met, with 5 out of 9 patients (56%) achieving a pathologic complete response (pCR)[76] - In the Phase 2 study for refractory melanoma, patient enrollment was temporarily suspended but resumed; however, the study was ultimately terminated with only 1 patient enrolled[77] - The Phase 1/2a trial for metastatic or unresectable triple negative breast cancer was terminated with 5 patients enrolled, indicating challenges in recruitment and funding[78] - A total of 42 pancreatic cancer patients received Ampligen treatment under the Expanded Access Program (EAP), with over 50 patients ultimately treated[81] - The median overall survival for patients treated with Ampligen in a named patient program was 19 months, significantly higher than historical controls (7.5 and 12.5 months)[88] - Ampligen demonstrated antiviral activity against SARS-CoV-2, suggesting potential as a treatment or prophylaxis against COVID-19[92] - The Phase 1/2a study of Ampligen and interferon alpha in cancer patients with COVID-19 plans to enroll up to 44 patients, with initial results reported by Roswell Park[95] - Ampligen demonstrated a 90% reduction in SARS-CoV-2 infectious viral yields at clinically achievable intranasal dosage levels in research conducted at Utah State University[96] - The AMP-511 Expanded Access Program for ME/CFS was expanded to include Long-COVID patients, with eight patients treated since January 2021[97] - A Phase 1 study of Ampligen showed no serious adverse events among 40 healthy subjects, supporting its potential as a prophylaxis or treatment for COVID-19[98] - Two provisional patent applications for Ampligen related to Post-COVID conditions were filed, with early data indicating improvements in fatigue symptoms[99] - The Phase 2 study AMP-518 enrolled 80 subjects, with topline data expected to show significant improvements in fatigue-related measures[102] Financial Position - AIM has reported a working capital deficit and stockholders' equity below the minimum requirement for continued listing on the NYSE American, raising concerns about its ability to continue as a going concern[27] - As of December 31, 2025, the stockholders' deficit was approximately ($9,783,000), necessitating an increase in stockholders' equity to at least $6,000,000 to regain compliance with listing standards[28] - A reverse stock split was authorized on a one-for-100 basis to help regain compliance with the NYSE American listing requirements[29] - The company has a history of losses and expects to continue incurring losses in the near term, raising substantial doubt about its ability to continue as a going concern[38] - The company may seek to raise additional funds, which could dilute existing ownership and negatively impact stock price[38] - The accumulated deficit was approximately $440,786,000 as of December 31, 2025, highlighting ongoing financial challenges and uncertainty regarding future profitability[159] - The company does not generate any material revenue from operations and does not anticipate doing so in the near future, necessitating further funding for product development[157] - The company has approximately $3,047,000 in cash, cash equivalents, and marketable securities, indicating a need for additional financing[157] - The company is currently not in compliance with the Exchange continued listing requirements, which could lead to delisting of its securities[38] - The company is not currently in compliance with the Exchange's listing requirements and has submitted a plan to regain compliance by June 11, 2026[141] - If the common stock is delisted, it may be subject to "penny stock" rules, which could limit trading activity and liquidity[144] - The company may face significant dilution of ownership if it raises additional funds through the issuance of equity securities[145] - The trading price of the common stock may be highly volatile and subject to wide fluctuations due to various factors beyond the company's control[150] - The company is classified as a "smaller reporting company," which may make its common stock less attractive to investors due to reduced disclosure requirements[155] - If the company is unable to obtain necessary regulatory approvals in a timely manner, its operations and stock price may be adversely affected[164] - The approval of Ampligen by the FDA remains uncertain, with potential delays and additional studies required that could extend the timeline for commercialization[170] Regulatory and Compliance - Ampligen received Orphan Drug Designation from the FDA for pancreatic cancer, providing seven years of market exclusivity upon approval[86] - The FDA granted clearance to proceed with a Phase 2 study for locally advanced pancreatic cancer after a previous clinical hold was lifted[85] - The FDA issued a Complete Response Letter for the NDA of Ampligen in February 2013, indicating that the submitted data did not provide substantial evidence of efficacy for the treatment of CFS[163] - Regulatory approval for Ampligen in Argentina has been received, but additional steps are required before commercial sales can commence[162] - The company has received Orphan Drug Designation from the FDA for Ampligen in treating multiple conditions, including Chronic Fatigue Syndrome and Ebola Virus Disease, which qualifies for various incentives[64] - The company has received approval from ANMAT for the commercial sale of Ampligen in Argentina for the treatment of severe CFS, with marketing to be conducted by GP Pharm (now Filaxis)[207] - The next steps for the commercial launch of Ampligen include a final inspection and release tests by ANMAT, which are currently delayed due to internal processes[208] Manufacturing and Production - The company has completed production of over 16,000 vials of Ampligen for multiple programs, including ME/CFS and pancreatic cancer treatment[57] - The validation of the polymer production process with Sterling Pharma Solutions is ongoing, necessary for future Ampligen manufacturing[58] - The production of new Alferon N Injection Active Pharmaceutical Ingredient is currently on hold, with no timeline for commercial availability[61] - The manufacturing process for Alferon N Injection is on hold, and there is no definitive timetable for its restart, which could materially affect operations[196] - The company is exploring engaging a Contract Manufacturing Organization (CMO) to produce Alferon active pharmaceutical ingredients (API) due to halted commercial sales from lack of finished goods inventory[196] - The company has limited manufacturing experience for Ampligen and Alferon N Injection, and profitability is contingent on producing these products in commercial quantities at acceptable costs[204] - There are limited suppliers available for raw and packaging materials necessary for the production of Ampligen and Alferon N Injection, which poses a risk to manufacturing capabilities[193] Market and Competition - The worldwide market for injectable alpha interferon-based products has seen rapid growth, with various products approved for major medical uses globally[60] - Alferon N Injection is the only natural-source, multi-species alpha interferon approved for sale in the U.S. and Argentina, specifically for treating refractory external genital warts in patients aged 18 and older[59] - Alferon N Injection has a low side-effect profile and no neutralizing antibodies observed to date, contrasting with recombinant formulations that may lose effectiveness after one year due to antibody formation[61] - The company faces significant competition from major pharmaceutical companies like Pfizer and Merck, which have greater financial resources and capabilities[132] - The company is pursuing licensing and collaboration strategies to make Ampligen available globally, targeting partners with strong commercial infrastructure and experience in relevant therapeutic areas[122] - The commercialization strategy for Ampligen may involve licensing or co-marketing agreements with strategic partners, with the goal of establishing a relationship before FDA approval[210] Risks and Challenges - The company has limited product liability and clinical trial insurance coverage, which may expose it to significant financial risks from product liability claims[166] - There is significant uncertainty regarding health care reimbursement for Ampligen and Alferon N Injection, which could impact the company's ability to realize returns on product development investments[167] - Ampligen's development is subject to risks including potential ineffectiveness, adverse side effects, and challenges in obtaining necessary regulatory approvals[175] - The company has not yet secured patents for Ampligen as a sole treatment for targeted cancers, which could hinder its marketability[185] - The patent landscape for biotechnology and pharmaceutical firms is complex and uncertain, with potential litigation that could drain resources[187] - The company has received various designations, including Orphan Drug Product Designation and "promising" clinical outcome recognition based on clinical reports[48] - The loss of key personnel could adversely affect the company's operations and ability to achieve its objectives[171] - The company has limited marketing and sales capabilities, relying on third-party distributors to generate significant revenues and achieve profitability[209]